{"id":473117,"date":"2021-04-07T14:12:22","date_gmt":"2021-04-07T18:12:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=473117"},"modified":"2021-04-07T14:12:22","modified_gmt":"2021-04-07T18:12:22","slug":"wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/","title":{"rendered":"Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">NEW YORK<\/span>, <span class=\"xn-chron\">April 7, 2021<\/span> \/PRNewswire\/ &#8212; Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of FibroGen, Inc. (NASDAQ: FGEN) common stock.<\/p>\n<p>FibroGen is a biopharmaceutical company. One of its lead drugs is roxadustat, which promotes red blood cell production. Roxadustat is currently approved for sale in <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">Japan<\/span> and <span class=\"xn-location\">Chile<\/span> for treatment of anemia for patients with chronic kidney disease. FibroGen submitted a New Drug Application (NDA) to the FDA for roxadustat in <span class=\"xn-chron\">December 2019<\/span>. On <span class=\"xn-chron\">March 1, 2021<\/span>, the FDA informed FibroGen that the Cardiovascular and Renal Drugs Advisory Committee would hold an advisory committee meeting to review the NDA for roxadustat. That news was unexpected and caused FibroGen&#8217;s stock price to fall almost 25% to <span class=\"xn-money\">$38.07<\/span> per share.<\/p>\n<p>After the market closed on <span class=\"xn-chron\">April 6, 2021<\/span>, FibroGen announced that while it was preparing for the Advisory Committee meeting, it became &#8220;aware that the primary cardiovascular safety analyses included post-hoc changes to the stratification factors&#8221; and that it \u00a0&#8220;promptly decided to clarify this issue with the FDA.&#8221; \u00a0Adam Feuerstein, the biotech reporter at STAT+, said &#8220;Fibrogen acknowledged Tuesday that the company has been touting false heart-safety data for its experimental anemia pill for at least two years \u2014 a shocking revelation that raises even more questions about the drug&#8217;s approvability.&#8221;<\/p>\n<p>In early morning trading on <span class=\"xn-chron\">April 7, 2021<\/span>, FibroGen&#8217;s stock price fell <span class=\"xn-money\">$12.42<\/span> per share to trade at <span class=\"xn-money\">$22.22<\/span>.<\/p>\n<p>For more information, FibroGen investors with trading losses of over <span class=\"xn-money\">$50,000<\/span> should contact <span class=\"xn-person\">Joshua Ruthizer<\/span> at (212) 451-9668 or at jruthizer<a target=\"_blank\" href=\"mailto:\" rel=\"nofollow noopener noreferrer\">mailto:<\/a>@wolfpopper.com.<\/p>\n<p>\n        <span class=\"xn-person\">Wolf Popper<\/span> has successfully recovered billions of dollars for defrauded investors.\u00a0 <span class=\"xn-person\">Wolf Popper&#8217;s<\/span> reputation and expertise have been repeatedly recognized by the courts, which have appointed the firm to major positions in securities litigation.\u00a0 For more information about <span class=\"xn-person\">Wolf Popper<\/span>, please visit the Firm&#8217;s website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3121767-1&amp;h=3387652700&amp;u=http%3A%2F%2Fwww.wolfpopper.com%2F&amp;a=www.wolfpopper.com\" rel=\"nofollow noopener noreferrer\">www.wolfpopper.com<\/a>.<\/p>\n<p>Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.<\/p>\n<p>Wolf Popper LLP<br \/><span class=\"xn-person\">Joshua W. Ruthizer<\/span><br \/>845 Third Avenue<br \/><span class=\"xn-location\">New York, NY<\/span> 10022<br \/>Tel.: (212) 451-9668<br \/>Email: <a target=\"_blank\" href=\"mailto:jruthizer@wolfpopper.com\" rel=\"nofollow noopener noreferrer\">jruthizer@wolfpopper.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC35158&amp;sd=2021-04-07\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock-301264381.html\">http:\/\/www.prnewswire.com\/news-releases\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock-301264381.html<\/a><\/p>\n<p>SOURCE  Wolf Popper LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DC35158&amp;Transmission_Id=202104071409PR_NEWS_USPR_____DC35158&amp;DateId=20210407\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK, April 7, 2021 \/PRNewswire\/ &#8212; Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of FibroGen, Inc. (NASDAQ: FGEN) common stock. FibroGen is a biopharmaceutical company. One of its lead drugs is roxadustat, which promotes red blood cell production. Roxadustat is currently approved for sale in China, Japan and Chile for treatment of anemia for patients with chronic kidney disease. FibroGen submitted a New Drug Application (NDA) to the FDA for roxadustat in December 2019. On March 1, 2021, the FDA informed FibroGen that the Cardiovascular and Renal Drugs Advisory Committee would hold an advisory committee meeting to review the NDA for roxadustat. That news was unexpected and caused FibroGen&#8217;s stock price &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-473117","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, April 7, 2021 \/PRNewswire\/ &#8212; Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of FibroGen, Inc. (NASDAQ: FGEN) common stock. FibroGen is a biopharmaceutical company. One of its lead drugs is roxadustat, which promotes red blood cell production. Roxadustat is currently approved for sale in China, Japan and Chile for treatment of anemia for patients with chronic kidney disease. FibroGen submitted a New Drug Application (NDA) to the FDA for roxadustat in December 2019. On March 1, 2021, the FDA informed FibroGen that the Cardiovascular and Renal Drugs Advisory Committee would hold an advisory committee meeting to review the NDA for roxadustat. That news was unexpected and caused FibroGen&#8217;s stock price &hellip; Continue reading &quot;Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-07T18:12:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC35158&amp;sd=2021-04-07\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock\",\"datePublished\":\"2021-04-07T18:12:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\\\/\"},\"wordCount\":350,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC35158&amp;sd=2021-04-07\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\\\/\",\"name\":\"Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC35158&amp;sd=2021-04-07\",\"datePublished\":\"2021-04-07T18:12:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC35158&amp;sd=2021-04-07\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC35158&amp;sd=2021-04-07\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/","og_locale":"en_US","og_type":"article","og_title":"Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock - Market Newsdesk","og_description":"PR Newswire NEW YORK, April 7, 2021 \/PRNewswire\/ &#8212; Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of FibroGen, Inc. (NASDAQ: FGEN) common stock. FibroGen is a biopharmaceutical company. One of its lead drugs is roxadustat, which promotes red blood cell production. Roxadustat is currently approved for sale in China, Japan and Chile for treatment of anemia for patients with chronic kidney disease. FibroGen submitted a New Drug Application (NDA) to the FDA for roxadustat in December 2019. On March 1, 2021, the FDA informed FibroGen that the Cardiovascular and Renal Drugs Advisory Committee would hold an advisory committee meeting to review the NDA for roxadustat. That news was unexpected and caused FibroGen&#8217;s stock price &hellip; Continue reading \"Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-07T18:12:22+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC35158&amp;sd=2021-04-07","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock","datePublished":"2021-04-07T18:12:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/"},"wordCount":350,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC35158&amp;sd=2021-04-07","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/","name":"Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC35158&amp;sd=2021-04-07","datePublished":"2021-04-07T18:12:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC35158&amp;sd=2021-04-07","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC35158&amp;sd=2021-04-07"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=473117"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473117\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=473117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=473117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=473117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}